N-{(2S)-5-[(4-methyl-2-pyridinyl)oxy]-2,3-dihydro-1H-inden-2-yl}-2-propanesulfonamide | 1162085-55-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: N-{(2S)-5-[(4-methyl-2-pyridinyl)oxy]-2,3-dihydro-1H-inden-2-yl}-2-propanesulfonamide
• 英文别名: N-[(2S)-5-(4-methylpyridin-2-yl)oxy-2,3-dihydro-1H-inden-2-yl]propane-2-sulfonamide
• CAS: 1162085-55-3
• 化学式: C₁₈H₂₂N₂O₃S
• 分子量: 346.45
• InChiKey: XBZNOWAESMBPKI-INIZCTEOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  24
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  76.7
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  2-溴-4-甲基吡啶 、 N-[(2S)-5-hydroxy-2,3-dihydro-1H-inden-2-yl]-2-propanesulfonamide 在 copper(l) iodide 、 N,N-二甲基甘氨酸 、 caesium carbonate 作用下， 以 二甲基亚砜 为溶剂， 反应 0.5h， 生成 N-{(2S)-5-[(4-methyl-2-pyridinyl)oxy]-2,3-dihydro-1H-inden-2-yl}-2-propanesulfonamide
  参考文献：
  名称：

  [EN] COMPOUNDS WHICH POTENTIATE THE AMPA RECEPTOR AND USES THEREOF IN MEDICINE
  [FR] COMPOSÉS POTENTIATEURS DU RÉCEPTEUR AMPA ET LEURS UTILISATIONS DANS LE DOMAINE MÉDICAL

  摘要：

  提供具有化学式（I）和其盐的化合物：其中n为0、1、2或3；R1从苯基和吡啶基中选择，每种基均可选择一个或两个独立选择自C1-4烷基和卤素的基进行取代；R2在n为1时从H和CH3中选择，而在n为2或3时R2为H。还公开了制备方法、药物组合物以及将其用作药物的用途，例如用于治疗由谷氨酸受体功能减少或失衡介导的疾病或症状，如精神分裂症或认知障碍。

  公开号：

  WO2009080637A1

文献信息

• Compounds which potentiate the AMPA receptor and uses thereof in medicine
  申请人：Glaxo Group Limited

  公开号：US08173820B2

  公开（公告）日：2012-05-08

  Compounds of formula (I) and salts thereof are provided: wherein n is 0, 1, 2 or 3; R1 is selected from phenyl and pyridyl, each of which is optionally substituted by one or two groups independently selected from C1-4alkyl and halogen; and R2 is selected from H and CH3 when n is 1 and R2 is H when n is 2 or 3. Processes for preparation, pharmaceutical compositions, and uses thereof as a medicament, for example in the treatment of a disease or condition mediated by a reduction or imbalance in glutamate receptor function, such as schizophrenia or cognition impairment, are also disclosed.

  提供了化学式（I）的化合物及其盐：其中n为0、1、2或3；R1选自苯基和吡啶基，每个基团可选择性地被一个或两个独立选择自C1-4烷基和卤素的基团取代；当n为1时，R2选自H和CH3，当n为2或3时，R2为H。还公开了制备过程、制药组合物和用作药物的用途，例如在治疗由谷氨酸受体功能降低或不平衡介导的疾病或症状，例如精神分裂症或认知障碍方面的用途。
• Compounds which Potentiate the AMPA Receptor and Uses Thereof in Medicine
  申请人：Bertheleme Nicolas

  公开号：US20110021578A1

  公开（公告）日：2011-01-27

  Compounds of formula (I) and salts thereof are provided: wherein n is 0, 1, 2 or 3; R 1 is selected from phenyl and pyridyl, each of which is optionally substituted by one or two groups independently selected from C 1-4 alkyl and halogen; and R 2 is selected from H and CH 3 when n is 1 and R 2 is H when n is 2 or 3. Processes for preparation, pharmaceutical compositions, N and uses thereof as a medicament, for example in the treatment of a disease or condition mediated by a reduction or imbalance in glutamate receptor function, such as schizophrenia or cognition impairment, are also disclosed.

  提供了式（I）的化合物和其盐：其中n为0、1、2或3；R1选自苯基和吡啶基，每个基团可选地被一个或两个独立选择的C1-4烷基和卤素取代；当n为1时，R2选自H和CH3，当n为2或3时，R2为H。还公开了制备方法、制药组合物、N和其作为药物的用途，例如在治疗由谷氨酸受体功能降低或失衡引起的疾病或症状，如精神分裂症或认知障碍中的用途。
• COMPOUNDS WHICH POTENTIATE THE AMPA RECEPTOR AND USES THEREOF IN MEDICINE
  申请人：Glaxo Group Limited

  公开号：EP2222632A1

  公开（公告）日：2010-09-01
• US8173820B2
  申请人：——

  公开号：US8173820B2

  公开（公告）日：2012-05-08
• [EN] COMPOUNDS WHICH POTENTIATE THE AMPA RECEPTOR AND USES THEREOF IN MEDICINE<br/>[FR] COMPOSÉS POTENTIATEURS DU RÉCEPTEUR AMPA ET LEURS UTILISATIONS DANS LE DOMAINE MÉDICAL
  申请人：GLAXO GROUP LTD

  公开号：WO2009080637A1

  公开（公告）日：2009-07-02

  Compounds of formula (I) and salts thereof are provided: wherein n is 0, 1, 2 or 3; R1 is selected from phenyl and pyridyl, each of which is optionally substituted by one or two groups independently selected from C1-4alkyl and halogen; and R2 is selected from H and CH3 when n is 1 and R2 is H when n is 2 or 3. Processes for preparation, pharmaceutical compositions, and uses thereof as a medicament, for example in the treatment of a disease or condition mediated by a reduction or imbalance in glutamate receptor function, such as schizophrenia or cognition impairment, are also disclosed.

  提供具有化学式（I）和其盐的化合物：其中n为0、1、2或3；R1从苯基和吡啶基中选择，每种基均可选择一个或两个独立选择自C1-4烷基和卤素的基进行取代；R2在n为1时从H和CH3中选择，而在n为2或3时R2为H。还公开了制备方法、药物组合物以及将其用作药物的用途，例如用于治疗由谷氨酸受体功能减少或失衡介导的疾病或症状，如精神分裂症或认知障碍。